CEACAM1, also known as biliary glycoprotein (BGP), CD66a, pp120 and C-CAM1, is a member of the CEA immunoglobulin superfamily. CEACAM1 is a putative tumor suppressor based on diminished expression in some solid neoplasms such as colorectal carcinoma. However, CEACAM1 is overexpressed in some tumors such as nonsmall cell lung cancer. To clarify the mechanism of action of this cell adhesion molecule, we studied thyroid carcinoma that has a spectrum of morphologies and variable behavior allowing separation of proliferation from invasion and metastasis. CEACAM1 is expressed in thyroid carcinoma cell lines derived from tumors that exhibit aggressive behavior. Introduction of CEACAM1 into endogenously deficient WRO cells resulted in reduced cell cycle progression associated with p21 upregulation and diminished Rb phosphorylation. Forced CEACAM1 expression enhanced cell-matrix adhesion and migration and promoted tumor invasiveness. Conversely, small interfering RNA (siRNA)-mediated downregulation of CEACAM1 expression in MRO cells accelerated cell cycle progression and significantly enhanced tumor size in xenografted mice. CEACAM1 is not appreciably expressed in normal thyroid tissue or benign thyroid tumors. In a human thyroid tissue array, CEACAM1 reactivity was associated with metastatic spread but not with increased tumor size. These findings identify CEACAM1 as a unique mediator that restricts tumor growth whereas increasing metastatic potential. Our data highlight a complex repertoire of actions providing a putative mechanism underlying the spectrum of biologic behaviors associated with thyroid cancer.
Introduction
Thyroid carcinomas derived from follicular epithelial cells represent a model of malignant transformation (Kondo et al., 2006) . They comprise a broad spectrum of neoplastic phenotypes ranging from benign adenomas and well-differentiated carcinoma to poorly differentiated thyroid carcinoma (PDTC) and the rare but rapidly lethal anaplastic (or undifferentiated) thyroid carcinoma (ATC) (DeLellis et al., 2004; Kondo et al., 2006) . Well-differentiated carcinoma is one of the most rapidly increasing malignancies with papillary thyroid carcinoma (PTC) more common than follicular thyroid carcinoma (FTC) in most parts of the world (DeLellis et al., 2004) . Several genetic molecular abnormalities have been associated with human thyroid carcinoma (Fagin, 1992; Kondo et al., 2006) . Of these, rearrangements of the RET tyrosine kinase (RET/PTC) and activating mutations of BRAF, a mediator of the tyrosine kinase-RAS signaling pathway, are the most common. However, RET rearrangements represent early events in thyroid tumorigenesis and are equally represented in incidental micropapillary carcinomas (Piersanti et al., 2003) and in clinically significant PTC (Sugg et al., 1998) . Moreover, mouse models carrying these genetic alterations develop thyroid tumors that do not typically display invasive or metastatic behavior (Jhiang et al., 1996; Powell et al., 1998) . Whereas BRAF mutations are associated with clinical PTC, they do not consistently predict invasion and/or metastasis. Ras mutations have been identified in rare well-differentiated thyroid carcinomas but are more common in poorly differentiated tumors that behave aggressively (Ezzat et al., 1996; Garcia-Rostan et al., 2001) . Additional genetic events have been identified in PDTC and ATC (Kondo et al., 2006) . However, a major clinical dilemma arises from the diagnosis of well-differentiated thyroid carcinoma, since only a small percentage of patients will develop metastases, but there is no reliable marker to separate those that need more aggressive management from the low-risk cases that will not manifest further sequelae. Thus, the identification of factors involved in modifying thyroid cancer behavior remains an important goal.
Many cancers display altered expression patterns of cell-matrix and cell-cell adhesion molecules. These changes serve to promote tumor progression and metastatic growth presumably through distinct interactions with surrounding extracellular matrix, control of cell proliferation and migration (Ruoslahti and Obrink, 1996) . Given the spectrum of biologic behavior displayed by thyroid carcinomas, we examined putative cell adhesion molecules in modulating thyroid carcinoma behavior.
Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 (CEACAM1), also known as biliary glycoprotein (BGP), CD66a and pp120, the human homolog of the rat C-CAM, is a member of the human carcinoembryonic antigen family, which belongs to the immunoglobulin superfamily of cell adhesion molecules. Located at chromosome 19q13.2 within the cluster of CEA-related genes (Olsen et al., 1994) , CEACAM1 is the most conserved member with one known gene in humans . This gene gives rise to alternatively spliced mRNA species with isoforms differing mostly in their cytoplasmic domains.
CEACAM1 is an example of a transmembrane protein widely expressed by epithelial and endothelial cells, and most types of hematopoietic cells tissues (Prall et al., 1996; Obrink, 1997; Singer et al., 2000; Plunkett and Ellis, 2002) . CEACAM1 shows both homophilic adhesion Ocklind, 1984 1446/id as well as heterophilic binding to other CEA family members in vitro (Oikawa et al., 1992) and is believed to be an important player in maintenance of normal tissue architecture. Several pathogens have also been shown to engage CEACAM1 in promoting their invasion and colonization of human mucosa (Muenzner et al., 2005) . CEACAM1-mediated signaling also promotes network formation on basement membrane and increases endothelial cell motility (Muller et al., 2005) .
In the current studies, we examined the expression of CEACAM1 in primary thyroid tumors and clonal cell lines representative of the different types of thyroid carcinomas. Using gain-and loss-of-function approaches in cell lines devoid and endowed with endogenous CEACAM1, respectively, we examined the functional impact of this putative adhesion factor on several parameters of growth associated with thyroid cancer behavior.
Results
CEACAM1 expression in human thyroid carcinoma cell lines CEACAM1 expression with two isoforms consistent with the L-CEACAM1 and S-CEACAM1 were detected in MRO (follicular) and ARO (anaplastic) thyroid cancer cells (Figure 1a) . No signal or a faintly detectable signal of the predicted size was identified by reverse transcriptase-polymerase chain reaction (RT-PCR) in the less aggressive TPC-1, NPA and WRO cell lines. The protein expression of CEACAM1 was investigated by Western blotting. As shown in Figure 1b , CEACAM1 protein corresponded with the RT-PCR data, and the predicted 130 kDa protein product of CEACAM1 was detected in MRO and ARO cells. Expression of CEACAM1 protein was undetectable in TPC-1, NPA and WRO cells. Immunolocalization confirmed CEA-CAM1 protein expression in MRO and ARO cells (Figure 1c ).
Functional impact of CEACAM1 on thyroid carcinoma cell growth
To examine the impact of CEACAM1 on thyroid cancer cell proliferation in vitro and tumorous growth in vivo, we established stable lines of CEACAM1-deficient WRO cells with forced expression of CEACAM1. We also examined the impact of attenuation of endogenous CEACAM1 expression in MRO cells using stable small CEACAM1 restores thyroid carcinoma cell-matrix adhesion CEACAM1 has been recognized as an intercellular adhesion molecule (Obrink, 1997) . However, its binding to extracellular matrix components has not clearly been defined. To investigate the impact of CEACAM1 on cell-matrix adhesion, we examined the effect of forced CEACAM1 expression on adhesiveness to a number of extracellular matrix components. CEACAM1 expression was associated with an overall increase in adhesion to extracellular matrices, an effect that was most evident 
CEACAM1 promotes thyroid carcinoma cell migration
Given the enhanced cell adhesiveness afforded by CEACAM1, we investigated the impact of CEACAM1 on cell migration on collagen IV and laminin surfaces. CEACAM1 expression was associated with measurably increased migration on both surfaces as depicted in Figures 3b and c.
CEACAM1 promotes thyroid carcinoma cell invasion
To investigate the effect of CEACAM1 on cell invasion, we examined independent clones of WRO cells with forced CEACAM1 expression using matrigel invasion assay. These studies demonstrated that CEACAM1 unequivocally promotes cell invasion (Figure 3d ). The impact of CEACAM1 under-expression could not be examined as MRO cells failed to invade through Matrigel. The latter finding suggests that CEACAM1 does not enhance invasion in general.
CEACAM1 modulates tumorous growth in xenografted mice
To study the impact of CEACAM1 on tumorous growth in vivo, we used a flank thyroid cancer xenograft model as previously described (Liu et al., 2005) . Tumor volume was significantly reduced in WRO cells with forced CEACAM1 expression compared to the control CEA-CAM1-negative cells ( Figure 4a ). Conversely, CEA-CAM1 silencing in MRO cells resulted in a measurable increase in tumor volume ( Figure 4b ). However, there was a striking change in tissue invasiveness attributable to CEACAM1 that could not be appreciated from tumor volume assessment alone. 
Discussion
The present study was performed to investigate the expression pattern and functional role of the cell adhesion molecule CEACAM1 in human thyroid carcinoma. We show here that CEACAM1 retards cell cycle progression to attenuate tumor size while promoting tissue invasiveness. The findings unmask a potential novel mechanism for identifying metastasizing thyroid carcinomas.
Cell adhesion molecules are not only involved in generating and maintaining normal tissue architecture and cellular polarity, but also play an important role in tumor invasion and progression (Hirohashi and Kanai, 2003) . Compared with normal tissues, malignant tumors are characterized by disruption of tissue architecture and deranged differentiation. It has been postulated that changes in cell-cell and cell-matrix interactions could account for the ability of cancer cells to cross tissue boundaries and to disseminate to distant sites. The loss of cell-cell binding that closely correlates with differentiation and the invasive potential of malignant tumors is accompanied by alteration in expression of cell adhesion molecules (Pignatelli and Vessey, 1994) . Dysregulated CEACAM1 protein expression in particular has been noted in several forms of solid neoplasia including breast (Obrink, 1997; Riethdorf et al., 1997; Plunkett and Ellis, 2002) , colorectal Brummer et al., 1995) , prostate Luo et al., 1999) , bladder (Kleinerman et al., 1996) , endometrial (Bamberger et al., 1998) and hepatocellular carcinomas (Takanishi et al., 1997) . More frequently, however, downregulation has been observed compared with adjacent non-malignant surrounding structures. This pattern has suggested a tumor suppressive role for CEACAM1. Indeed introduction into tumor cells derived from these carcinomas has been shown to slow tumor progression. For example, human prostate and colon cancer cells show diminished tumorigenesis when transfected with CEACAM1 (Hsieh et al., 1995; Kunath et al., 1995; Luo et al., 1999; Busch et al., 2002) .
In contrast to the putative tumor suppressive functions, CEACAM1 is not expressed in several normal epithelial tissues (Prall et al., 1996) , including thyroid as shown by our current studies. It has also been found to be upregulated in primary lung carcinomas when compared with adjacent normal lung tissue (Ohwada et al., 1994; Wang et al., 2000) . This upregulation appears to be associated with increased metastatic potential. Similar upregulation has been noted in gastric adenocarcinoma (Kinugasa et al., 1998) and cutaneous malignant melanoma (Thies et al., 2002) . These latter observations have been interpreted as evidence for an oncogenic function for CEACAM1.
The CEACAM1 gene contains nine exons encoding a transmembrane protein. Exon 1 encodes the leader sequence, exons 2-5 encode a variable immunoglobulinlike N terminal domain followed by up to three repeats of immunoglobulin constant-like A or B domains followed by a transmembrane domain encoded by exon 6 and an alternative cytoplasmic domain (exon 7-9) (Barnett et al., 1993) . Insertion of exon 7, comprised of 53 bp, results in the translation of a longer cytoplasmic domain of 71-73 amino acids (CEACAM1-L). The shorter form (CEACAM1-S) of CEACAM1 includes a cytoplasmic tail of only 10 residues. Structural and functional analyses have suggested that the adhesive activity of CEACAM1 is mediated by the first extracellular immunoglobulin domain while the cytoplasmic domain is necessary and sufficient for growth regulatory functions (Fournes et al., 2001 (Izzi et al., 1999; Estrera et al., 2001; Fournes et al., 2001) . Point mutation of Tyr-488 was sufficient to reverse the in vivo tumor growth inhibition while substitution or deletion of Ser-503 leads to reversal of tumor inhibition (Izzi et al., 1999) . Although phosphorylation of CEACAM1 appears to be critical in the control of proliferative functions, mutation of Tyr-488 alone has been described not to abolish tumor suppressive actions (Estrera et al., 2001) . Transfection of the cytoplasmic domain alone was sufficient to cause tumor suppression (Estrera et al., 1999) consistent with a putative tumor suppressive role for CEACAM1-L.
Thyroid cancer represents a unique model to dissect the proliferative and metastatic functions of CEACAM1 that may help explain some of the previous paradoxical features noted in other malignancies. Well-differentiated thyroid carcinoma is endowed with growth promoting properties that give rise to a clinically palpable nodule. Only less than 20% of these nodules manifest metastatic spread, usually to local lymph nodes. The growth and metastatic potentials are not necessarily associated, as exemplified by occult papillary microcarcinomas that metastasize. There are currently no histopathological and few immunohistochemical or molecular markers that can distinguish these two properties of this neoplasm. This situation has resulted in a clinical dilemma for the rational therapy of low-risk thyroid carcinoma. Our data illustrate a unique expression pattern for CEACAM1 and a mechanism of action that may clarify this discrepancy. While not appreciably expressed in normal human thyroid tissue and rarely in benign tumors, CEACAM1 is significantly upregulated in thyroid carcinomas, particularly in metastatic tumors. Moreover, there is a clear dissociation between CEA-CAM1-mediated metastatic potential and growth that may clarify the mechanism of spread in small tumors.
To investigate the role of CEACAM1 in thyroid carcinomas, we chose to use WRO cells, which are usually devoid of CEACAM1 expression, to compare the effects of CEACAM1 in control cells and clones with forced CEACAM1 expression. We also used MRO cells with strong endogenous CEACAM1 protein expression to examine the effects of silencing of expression of this protein. In vitro, FACS analysis revealed that forced expression of CEACAM1 caused a significant G0/G1 phase arrest. Moreover, CEACAM1 expression resulted in enhanced cell-matrix adhesion as well as increased cell invasion. The combined impact of these properties was associated with diminished tumor progression in xenografted mice. In a xenograft model, CEACAM1 expression resulted in diminished tumor growth but increased tumor invasiveness. Conversely, downregulation of CEACAM1 significantly stimulated MRO cell tumor growth with reduced invasiveness. These findings clearly define CEACAM1 as an important inhibitor of cell proliferation and tumor growth but as a mediator of invasion.
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Cell cycle progression is regulated by cyclins, cyclindependent kinases (CDKs) and CDK inhibitors (CDKIs). The CDKIs p21 and p27 are implicated in thyroid neoplasia (Khoo et al., 2002a, b; Kondo et al., 2006) . To further explore the mechanism of cell cycle regulation by CEACAM1, we examined the effect of CEACAM1 on p21 and p27 expression both in cultured cells and in mouse xenografts using immunohistochemistry or Western immunoblotting. The results showed that CEACAM1 significantly enhanced p21 but not p27 expression and conversely downregulation of CEA-CAM1 decreased p21 but not p27 expression. These data are in partial agreement with a recent report where CEACAM1 depletion was shown to be associated with diminished p21 and p27 in mouse colonic epithelium (Leung et al., 2006) .
In summary, we have demonstrated here that CEACAM1, a member of the human carcinoembryonic antigen family, is principally expressed in aggressive thyroid carcinomas. However, instead of promoting growth, we show that CEACAM1 functions to retard several parameters of neoplastic growth and to enhance cell-matrix adhesion. This finding is consistent with the expression of CEACAM1 in extravillous intermediate trophoblast where it has been functionally implicated in mediating trophoblast/endometrial interactions during trophoblastic invasion of the endometrium (Bamberger et al., 2000 (Bamberger et al., , 2006 , and with its correlation with invasion in cutaneous malignant melanoma (Thies et al., 2002; Ebrahimnejad et al., 2004) . These findings can be reconciled by a model in which upregulation of CEACAM1 during cell transformation may reflect a mechanism serving to impede further growth at the expense of promoting metastatic behavior.
Materials and methods
Cell lines and cell culture TPC-1 cells (a gift from Dr SM Jhiang, Ohio State University, Columbus, OH, USA), derived from a well-differentiated papillary thyroid carcinoma with a ret/PTC gene rearrangement, were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% FBS, 2 mmol/l L-glutamine. NPA cells, a papillary carcinoma cell line with homozygous BRAF mutations, WRO and MRO follicular carcinoma cell lines and ARO anaplastic thyroid carcinoma cell line were obtained from Dr J Fagin (University of Cincinnati, Cincinnati, OH, USA) and were maintained in RPMI 1640 supplemented with 10% FBS, 2 mmol/l L-glutamine, 1 mmol/ l sodium pyruvate, and 1 Â nonessential amino acid (SigmaAldrich, Irvine, UK). Cells were all cultured in a standard humidified incubator at 371C in a 5% CO 2 atmosphere. Cell viability was assessed using Trypan blue exclusion before and after all experiments.
RNA extraction and analysis Total RNA was isolated from cells with TriZol reagent (Invitrogen Corp., Carlsbad, CA, USA) according to the manufacturer's instructions. Approximately 1.5 mg of total RNA from each sample was used to conduct reverse transcription reaction in a 30 ml volume using TaqMan reverse transcription reagents kit (Applied Biosystems Inc., Branchburg, NJ, USA). The reaction mixture was incubated at 251C for 10 min, 481C for 30 min and 951C for 5 min. The synthesized cDNA was used for PCR amplification or stored at À201C for further analysis.
PCR primers were designed to amplify the long (CEA-CAM1-L) (408-bp) and short (CEACAM1-S) (355-bp) forms of CEACAM1 cDNA. The forward primer, 5 0 -GGTTGCTCTGATAGCAGTAG-3 0 , is situated in the transmembrane domain (exon 6), and the reverse primer, 5 0 -AGCCTGGAGATGCCTATTAG-3 0 , is situated within the 3 0 untranslated region. The PCR reaction was performed in a 20 ml volume containing 4.0 ml RT reaction mixture of 0.5 mM of each primer, 1 Â PCR buffer, 3.0 mM MgCl 2 and 2.5 U AmpliTaq DNA polymerase (PE Applied Biosystems, Foster City, CA, USA). Reaction conditions included initial denaturation at 941C for 2 min, followed by 35 cycles at 941C for 1 min, annealing at 551C for 1 min and extension at 721C for 1 min, followed by a 10 min final extension at 721C. PCR products were separated on 2.0% agarose gels and visualized by ethidium bromide staining. The quality of the total RNA and RT reaction were determined by PCR for the house-keeping gene PGK-1 (sense strand: 5 0 -CAGTTTGGAGCTCCTGGAAG-3 0 and antisense strand: 5 0 -TGCAAATTCAGGGTGCAGTG-3 0 ). The PCR reaction contained 2.0 ml of cDNA, 0.8 mM of each primer, 1 Â PCR buffer, 2.0 mM MgCl 2 , and 2.5 U AmpliTaq DNA polymerase (PE Applied Biosystems, Foster City, CA, USA) in a final volume of 20 ml using the following conditions: 951C for 5 min, 34 cycles of 941C for 30 s, 571C for 30 s, and 721C for 1 min and a 7 min final extension at 721C.
Protein isolation and Western immunoblotting
Cells were lysed in lysis buffer (0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1% Nonidet P-40 and 1 Â PBS) containing proteinase inhibitors (100 mg/ml phenylmethylsulfonyl fluoride (PMSF), 69 mg/ml aprotinin (Sigma, St Louis, MO, USA), and 1 mM sodium orthovanadate. Total cell lysates were incubated on ice for 30 min, followed by micro-centrifugation at 10 000 g for 10 min at 41C. Protein concentrations of the supernatants were determined by the Bio-Rad protein assay.
Equal amounts of protein (50 mg) were mixed with 2 Â SDS sample buffer, boiled for 4 min and separated by 10% SDSpolyacrylamide gel electrophoresis, and transferred onto nitrocellulose membranes (Bio-Rad laboratories, Hercules, CA, USA). Non-specific binding was blocked with 5% nonfat milk in 1 Â TBST (tris-buffered saline with 0.1% Tween-20). Primary antibodies and antisera were directed against CEA-CAM1 (monoclonal 4D1/C2) (Stoffel et al., 1993) (1:1000), p21 (polyclonal 1:500, BD Biosciences, Mississauga, Canada), p27 (monoclonal 1:1000, Transduction Laboratories, Lexington, KY, USA), phospho-Rb (Ser780, polyclonal 1:1000, Cell Signaling Technology, Beverley, MA, USA) or actin (monoclonal 1:500, Sigma, St Louis, MO, USA). After washing three times each for 10 min in 1 Â TBST, blots were exposed to the secondary antibody (anti-mouse or anti-rabbit IgG-HRP, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) at a dilution of 1:2000 and visualized using ECL chemiluminescence detection system (Amersham, Buckinghamshire, UK). Band intensities were quantified by densitometry.
CEACAM1 silencing or overexpression in human thyroid carcinoma cells
The hairpin siRNAs of human CEACAM1 were designed using Ambion software according to the manufacturer's 0 . The expression vector pSilencer 2.1-U6 neo-siCEACAM1 was constructed according to the manufacturer's instructions. Ligation of the vector and oligo was performed with 1 ml of vector, 1 ml of oligo, 2 ml of 10 Â T4 DNA ligase buffer, 3 ml of T4 DNA ligase for 5 min at room temperature. Three microlitres of ligation reaction was then used to transform DH5a Esherichia coli. Clones containing the oligo inserts were identified by restriction enzyme digestion and by DNA sequencing. Plasmid DNA for transfection was prepared using the QIAGEN Maxi Kit (QIAGEN, Mississauga, Canada) .
WRO cells which did not endogenously express CEACAM1 were selected for stable forced expression of CEACAM1-L using the pcDNA 3.1(À)/Zeo-L-CEACAM1 expression vector as described previously (Briese et al., 2005) . Empty vector served as a control. Conversely, MRO cells which did express endogenous CEACAM1 were transfected with CEACAM1 siRNA following the Lipofectamine protocol as recommended by the manufacturer (Invitrogen). A circular pSilencer2.1-U6 neo-vector that expresses a hairpin siRNA without homology to any known sequences in the human, mouse and rat genomes was used as a negative control. Cell populations that stably express the siRNA for sustained knockdown experiments were identified by neomycin selection. Specific forced expression and reduction of targeted CEACAM1 expression was confirmed by Western blotting analysis with the anti-CEACAM1 antibody 4D1/C2 (Stoffel et al., 1993) .
Cell cycle analysis
For cell cycle assessment cells were starved in serum-free growth medium for 24 h before being exposed to growth medium containing 10% FBS for another 24 h. After trypsinization, cells were washed with D-PBS (Ca 2 þ -Mg 2 þ -free) and fixed with cold 80% ethanol for 1 h on ice. Fixed cells were washed with staining buffer (0.2% Triton X-100 and 1 mM/l EDTA, pH 8.0, in PBS) and resuspended in the staining buffer containing 50 mg/ml DNase-free RNase A (Sigma) and 50 mg/ml propidium iodide for 1 h. Cell-cycle analysis was performed by fluorescence-activated cell sorting (FACS; Becton Dickinson, San Jose, CA, USA) using Cellquest analysis and specific S phase was analysed using Modfit DNA Analysis (Verity Software House Inc., Topsham, ME, USA).
Adhesion assay
After trypsinization, an equal number (1 Â 10 5 ) of WRO cells expressing CEACAM1 and control cells were plated in each well of 24-well plates coated with collagen I, collagen IV, fibronectin or laminin (BD Biosciences, Bedford, MA, USA) and incubated for 1 h, then rinsed with PBS four times. The remaining cells in each well were fixed in 10% buffered formalin for 20 min at room temperature, washed in PBS and the entire field counted with a stereomicroscope. All images were recorded and analysed using Image-Pro Plus Software (version 4.5; Media Cybernetics Inc., Silversprings, MD, USA).
Migration assay
Control and CEACAM1-transfected WRO (0.5 Â 10 6 ) cells were plated on collagen IV-and laminin-coated six-well plates (BD Biosciences). After reaching confluence, cells were gently scratched with a standard 200 ml tip, rinsed three times, and returned to cell incubator after growth medium was replaced. Cells were permitted to migrate into the area of clearing and photomicrographied at 0, 6 and 12 h using an Axiovert 200 M phase-contrast microscope (Zeiss Axiovert S100TV, Leipzid, Germany). Migrating areas were analysed using Image-Pro Plus Software.
Invasion assay
BioCoat Matrigel Invasion Chambers (BD Biosciences) were allowed to reach room temperature. Warm (371C) RPMI 1640 medium was added to the interior of the inserts (0.5 ml/each) and bottom of the wells (0.5 ml/well). Rehydration for 2 h in humidified culture incubator (371C, 5% CO 2 atmosphere) was followed by careful removal of media without disturbing the layer of Matrigel Matrix on the membrane.
After trypsinization, an equal number (2.0 Â 10 4 ) of WRO cells expressing CEACAM1 and control cells in 0.5 ml of serum-free RPMI 1640 medium containing 0.2% BSA were plated in each insert. The growth medium containing 5% FBS was used as a chemoattractant in the bottom well.
Following 24 h of incubation, non-invading cells were removed from the upper surface of the membrane by scrubbing with a cotton swab. Cells on the lower surface of the membrane were stained with Diff-Quik Stain (BD Biosciences). Staining was accomplished by sequentially transferring the inserts through three solutions. After airdrying, the membrane was removed from the insert and invading cells photographed under the microscope for quantitation.
Mouse xenograft studies
To assess tumor formation, 5 Â 10 6 cells were injected subcutaneously into the flank of 6-week-old SCID mice. Tumor volume was monitored every 5 days as previously described (Liu et al., 2005) . Mice were killed 21 days following tumor cell implantation and the tumors were excised, weighed and measured. Excised tumor tissue was fixed in formalin and embedded in paraffin for light microscopy and immunohistochemical staining. Animal handling protocol was approved by the Ontario Cancer Institute Animal Care and Utilization Committee.
Human thyroid tumor specimens Formalin-fixed, paraffin-embedded tissues from 230 patients who underwent thyroid surgery at the University Health Network (UHN) Hospitals between 2001 and 2004 were used for tissue array construction. From the surgical specimens of these 230 patients, a total of 297 distinct samples were obtained, including 94 benign samples and 203 malignant samples (Table 1) . Each patient was represented by one tumor sample, with 67 additional samples taken from these patients for the complete (n ¼ 230 þ 67 ¼ 297) array assessment. The additional samples were lymph node metastases of 35 patients with primary tumors in the array, and multiple lymph node metastases of two patients, two different neoplastic nodules in seven patients with multifocal disease, normal thyroid tissue in 20 patients (five benign, 15 malignant), foci of nodular hyperplasia in two patients, and anaplastic metastasis from a primary papillary carcinoma. Data on tumor characteristics and prognostic factors were obtained from the surgical pathology reports. All patient samples and related data CEACAM1 in thyroid cancer W Liu et al analyses were performed in accordance with research ethics approval at the University Health Network in Toronto.
Thyroid tissue array
The regions of interest were carefully identified on H&E-stained slides, and then marked directly on the corresponding donor blocks. One mm diameter cylindrical cores were taken from each donor block and arrayed at 2.0 mm intervals (from core center to center) using a manual tissue arrayer (Beecher Instruments, Silver Spring, MD, USA). Three cores for each desired sample (benign or malignant) were arrayed, yielding a total of 297 Â 3 or 891 cores. Ten recipient blocks were constructed. Normal thyroid controls were represented in all blocks.
Immunohistochemistry Cultured cells were washed in cold D-PBS (Ca 2 þ -Mg 2 þ -free) three times, gently scraped off and centrifuged into pellets that were coated in 2% bactoagar until solidified. These pellets were fixed in 10% formalin, and embedded in paraffin.
Four-micron-thick sections cut from cell pellets, harvested xenografted tumors or paraffin-embedded tissue microarray blocks were de-waxed in five changes of xylene and rehydrated through graded alcohols into water. Sections were then microwave-heated in 10 mM citrate buffer at pH 6.0 inside a pressure cooker as previously optimized. Endogenous peroxidase and biotin activities were blocked, respectively, using 3% hydrogen peroxide and Vector's avidin/biotin blocking kit (Vector Laboratories Inc., Burlingame, CA, USA). Sections were treated for 10 min with protein blocker (ID Labs Inc., London, ON, Canada) and then incubated overnight with primary antibody or antiserum. The primary reactions were as follows: anti-CEACAM1 mouse monoclonal antibody (4D1/ C2) at 1:200; monoclonal anti-MIB-1 antibody (Immunotech, Marseilles, France) at 1:600; p21 (BD Biosciences) at 1:300; p27 (BD Transduction Laboratories) at 1:1000. This incubation was followed by 30 min each with biotinylated linking reagent (ID Labs Inc.) and HRP-conjugated Ultra Streptavidin Labeling Reagent (ID Labs Inc.). Color development was performed with freshly prepared NovaRed solution (Vector Labs Inc.) and counterstained with Mayer's hematoxylin. Finally, sections were dehydrated through graded alcohols, cleared in xylene and mounted in Permount (Fisher, Ontario, Canada).
Tissue array scoring
Positive staining was based on the distribution and intensity of distinct membrane or cytoplasmic signals in each core using the following criteria. The percentage of cells staining was scored as 0 (0%), 1 (1-50%) or 2 (51-100%), and then averaged for each sample to form a distribution score. Next, the intensity of signal was scored in each core as 0 (no signal), 1 (weak), 2 (moderate) or 3 (marked) and then averaged for each sample to form an intensity score. The total of the distribution score and intensity score was summed for each sample into a total score (TS), which was indicated as negative (TSp2), weakly positive (2oTSp3) or positive (TS>3).
In samples where one of the three cores was not interpretable (6/297 samples ¼ 2.0%, due to either insufficient cells or loss of the core during array slide processing), the distribution and intensity scores were based on the average of the remaining two cores. All cores were scored by one investigator (DW) and verified by a second independent investigator (SLA).
Statistical analysis
Data were assessed by Student's t-test. Differences in two proportions were calculated using the Fisher's exact test. Significance level for all tests was assigned at Po0.05.
